Yousefpour P, Gosh AR, Chawla H, Gregory J, Yeung R, Remba T, Silva M, Xiao X, Melo M, Abraham W, Crispin M, Batista F, Irvine DJ. Impact of the antigen expression form on immune responses to self-replicating RNA vaccines. (Submitted)

​

Yousefpour P, Lonzaric J, Li Y, Lemnios A, Gregory J, Qureshi K, Remba T, Yeung R, Adams J, Weiss R, Irvine DJ. Small molecule-based regulation of RNA amplification and transgene expression for immunotherapy. (Submitted) 

​

Yousefpour P, Zhang YJ, Maiorino L, Melo MB, Arainga Ramirez MA, Kumarapperuma SC, Xiao P, Silva M, Li N, Michaels KK, Georgeson W, Eskandarzadeh S, Kubitz M, Groschel B, Qureshi K, Fontenot J, Hangartner L, Nedellec R, Love JC, Burton DR, Schief WR, Villinger FJ, Irvine DJ. Modulation of antigen delivery and lymph node activation in non-human primates by saponin adjuvant SMNP. PNAS Nexus. 2024; 3(12), 529.

​

Rodrigues KA, Zhang YJ, Aung A, Morgan DM, Maiorino L, Yousefpour P, Gibson G, Ozorowski G, Gregory JR, Amlashi P, Buckley M, Ward AB, Schief WR, Love JC, Irvine DJ. Vaccines combining slow delivery and follicle targeting of antigens increase germinal center B cell clonal diversity and clonal expansion. (Submitted)

​

Yousefpour P, Ni K, Irvine DJ. Targeted modulation of immune cells and tissues using engineered biomaterials. Nature Review Bioengineering. 2023; 1:107–124.

​

Rodrigues, KA, Cottrel CA, Steichen JM, Groschel B, Abraham W, Suh H, Agarwal Y, Ni K, Chang JYH, Yousefpour P, Melo MB, Schief, WR, Irvine DJ. Optimization of an alum-anchored clinical HIV vaccine candidate. npj Vaccines. 2023; 8 (1), 117.

​

Ma L, Hostetler A, Morgan DM, Maiorino L, Sulkaj I, Whittaker CA, Neeser A, Pires IS, Yousefpour P, Gregory J, Qureshi K, Dye J, Abraham W, Suh H, Li N, Love JC, Irvine DJ. Vaccine-boosted CAR T crosstalk with host immunity to reject tumors with antigen heterogeneity. Cell. 2023; 186 (15), 3148-3165.

​

Yousefpour P, Varanko A, Subrahmanyan R, Chilkoti A. Recombinant fusion of glucagon‐like peptide‐1 and an albumin binding domain provides glycemic control for a week in diabetic mice. Advanced Therapeutics. 2020; 2000073.

​

Banskota S, Saha S, Bhattacharyya J, Kirmani N, Yousefpour P, Dzuricky M, Zakharov N, Li X, Spasojevic I, Young K, Chilkoti A. Nano Letters. 2020; 20(4): 2396–2409.

​

Dodd RD, Scherer A, Huang W, McGivney GR, Gutierrez WR, Laverty EA, Ashcraft KA, Stephens VR, Yousefpour P, Saha S, Knepper-Adrian V, Floyd W, Chen M, Ma Y, Mastria EM, Cardona DM, Eward WC, Chilkoti A, Kirsch DG. Tumor subtype determines therapeutic response to chimeric polypeptide nanoparticle–based chemotherapy in Pten-deleted mouse models of sarcoma. Clinical Cancer Research. 2020; CCR-19-2597.

​

Wang J, Saha S, Schaal JL, Yousefpour P, Li X, Chilkoti A. Heuristics for the optimal presentation of bioactive peptides on polypeptide micelles. Nano Letters. 2019; 19(11):7977-7987.

​

Yousefpour P, Ahn L, Tewksbury J, Bellucci JJ, Saha S, Li X, Chilkoti A. Conjugate of doxorubicin to albumin binding peptide outperforms aldoxorubicin. Small. 2019; 15(12):1804452.

​

Banskota S, Yousefpour P, Kirmani N, Li X, Chilkoti A. Long circulating genetically encoded intrinsically disordered zwitterionic polypeptides for drug delivery. Biomaterials. 2019; 192: 475-485.

​

Yousefpour P, McDaniel JR, Prasad V, Ahn L, Li X, Subrahmanyan R, Weitzhandler I, Suter S, Chilkoti A. Genetically encoding albumin binding into chemotherapeutic-loaded polypeptide nanoparticles enhances their antitumor efficacy. Nano Letters. 2018; 18(12): 7784–7793.

​

Luginbuhl KM, Mozhdehi D, Dzuricky M, Yousefpour P, Huang FC, Mayne NR, Buehne KL, Chilkoti A. Recombinant synthesis of hybrid lipid–peptide polymer fusions that self-assemble and encapsulate hydrophobic drugs. Angewandte Chemie. 2017; 56(45): 13979.

​

Banskota S*, Yousefpour P*, Chilkoti A. Cell-based biohybrid drug delivery systems: the best of the synthetic and natural worlds. Macromolecular Bioscience. 2017; 17(1): 1600361. *Co-first authors.

​

Yousefpour P, Chilkoti A. Co-opting biology to deliver drugs. Biotechnology and Bioengineering. 2014; 111(9): 1699. 

​

Yousefpour P, Atyabi F, Vasheghani-Farahani E, Mousavi-Movahedi A, Dinarvand R. Targeted delivery of doxorubicin- utilizing chitosan nanoparticles surface-functionalized with anti-HER2 trastuzumab. Int. J. Nanomedicine. 2011; 6: 1977. 

​

Yousefpour P, Atyabi F, Vasheghani-Farahani E, Sakhtianchi R, Dinarvand R. Polyanionic carbohydrate doxorubicin–dextran nanocomplex as a delivery system for anticancer drugs: in vitro analysis and evaluations. Int. J. Nanomedicine. 2011; 6: 1487. 

​

Yousefpour P, Atyabi F, Dinarvand R, Vasheghani-Farahani E. Preparation and comparison of chitosan nanoparticles with different degrees of glutathione thiolation. Daru. 2011; 19(5): 367.